Piramal Enterprises dispels rumours about financial biz, files complaint with Sebi Certain market participants are spreading false/misleading rumours against the company's financial services business in an attempt to create panic among various stakeholders, it said in a regulatory filing.
Natco Pharma gets EIR from USFDA for Hyderabad facility In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
Brokerages initiate coverage on these 8 stocks in September, expect 13-52% return The market is likely to remain in a tight range due to lack of domestic triggers as well as mixed global cues," Siddhartha Khemka, Head - Retail Research at MOFSL told Moneycontrol.
Rupee headwinds will put pressure on equities; could retest Rs 74/$ in near term Rupee successfully retested its multi-year breakout zone of 69 and is poised to retest its previous zone of Rs 74.5/$ and could even breach it
Stocks in the news: RIL, Tata Motors, ONGC, BHEL, BPCL, Sintex Plastics, Varroc Engg, Oil India Tata Motors | Alembic | Bosch | National Aluminium Company | Unichem Laboratories | ONGC | BHEL | BPCL and Sintex Plastics are among stocks, which are in news today.
Natco Pharma gets EIR from USFDA for Kothur facility The receipt of EIR from the United States Food and Drug Administration (USFDA) indicates the successful closure of inspection of the company’s drug formulations facility in Kothur, Natco Pharma said in a BSE filing.
Buy Piramal Enterprises; target of Rs 2400: Motilal Oswal Motilal Oswal is bullish on Piramal Enterprises has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated July 30, 2019.
Pfizer’s Upjohn-Mylan merger may have little impact on India operations As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.
Piramal Enterprises Q1 net up 21% at Rs 461 cr Net sales rose 21 per cent to Rs 3,506 crore in the latest quarter as against Rs 2,902 crore in June quarter 2018-19, Piramal Enterprises said in a statement.
Piramal Capital eyes buyouts worth $600m in NBFC space; targets DHFL’s porfolio: Report In June, Piramal Enterprises sold its entire stake (nearly 10 percent) in Shriram Transport Finance to institutional investors for Rs 2,300 crore